Cetera Investment Advisers’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Cetera Investment Advisers’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,800	Closed	-$146K	–	2266
2022 Q4	$146K	Buy	+13,800	New	+$111K	﹤0.01%	1951
2022 Q3	–	Sell	-13,800	Closed	-$55K	–	1893
2022 Q2	$55K	Hold	13,800	–	–	﹤0.01%	1764
2022 Q1	$101K	Hold	13,800	–	–	﹤0.01%	1798
2021 Q4	$78K	Hold	13,800	–	–	﹤0.01%	1809
2021 Q3	$88K	Hold	13,800	–	–	﹤0.01%	1745
2021 Q2	$116K	Buy	13,800 +3,605	+35%	+$29.1K	﹤0.01%	1718
2021 Q1	$107K	Buy	+10,195	New	+$143K	﹤0.01%	1549

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Cetera Investment Advisers's PRVB Position: Q1 2023 in Review

Cetera Investment Advisers sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 13,800 shares — an estimated $146K sold.

Cetera Investment Advisers first reported a position in PRVB in Q1 2021 and held it in 7 quarters. The position peaked at $146K in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

Cetera Investment Advisers reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Cetera Investment Advisers sold 13,800 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $146K.
Cetera Investment Advisers first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Cetera Investment Advisers's Provention Bio, Inc. Common Stock position peaked at $146K in Q4 2022.
182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Cetera Investment Advisers's 13F filing for Q1 2023, filed 15 May 2023.